Company / Cash & Equivalents
Bio-Rad Laboratories Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$529.8M
FY2025
5-year range
$403.8M / $529.8M
FY2021-FY2025
Trend
+8.5%
vs FY2024
Sector context
#45 of 148
Health Care
What the data says
At $530M, Bio-Rad Laboratories's cash & equivalents ranks #45 of 148 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $384M in FY2018 to $661M in FY2020.
Based on SEC 10-K filings.
$530M in FY2025 with a 5-year CAGR of -4.3%.
Improved from $404M to $530M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +6.9%
- 5-Year CAGR
- -4.3%
- 10-Year CAGR
- -
Sector benchmark
#45 of 148 in Health CareTop 30% of 148This company $529.8M Sector average $1.2B
▼
-55.0% below sector average
Key checks
Key Insights
- 5-year CAGR of -4.3%, indicating a declining trend.
- In FY2025, cash & equivalents increased 8.5% year-over-year.
- Ranks #45 out of 148 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2020.
Company context
Key Data Points
- Strong return on equity: 23.0%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $529.8M | +8.5% |
| FY2024 | $488.1M | +20.9% |
| FY2023 | $403.8M | -7.0% |
| FY2022 | $434.2M | -7.8% |
| FY2021 | $470.8M | -28.7% |
| FY2020 | $660.7M | +0.0% |
| FY2019 | $660.7M | +72.1% |
| FY2018 | $383.8M | -15.9% |
| FY2017 | $456.3M | +10.4% |
| FY2016 | $413.3M | -9.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026